Carvedilol suppresses circulating and hepatic IL-6 responsible for hepatocarcinogenesis of chronically damaged liver in rats

Balaha, Mohamed; Kandeel, Samah; Barakat, Waleed

doi:10.1016/j.taap.2016.10.012

Cited by 17 publications

(12 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antioxidant effect of CAR may contribute to its cancer-preventive activity. Although the present study focused on breast cancer prevention, the results may lay the foundation for clinical trials that can be designed to prevent other types of cancer, as reported recently in the prevention of hepatocarcinogenesis (36).…”

Section: Discussionmentioning

confidence: 86%

Carvedilol suppresses malignant proliferation of mammary epithelial cells through inhibition of the ROS‑mediated PI3K/AKT signaling pathway

Liu

Zhang

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

Reactive oxygen species (ROS) cause oncogenic mutations through direct interaction with DNA. Carvedilol (CAR) exhibits antioxidative activity, and pre-clinical studies have identified that CAR may prevent malignant transformation in certain carcinogenic models. This suggests that CAR may be a potential agent in cancer prevention. In the present study, non-cancerous MCF-10A cells were used as a model to investigate the chemopreventive effect of CAR on benzo(a)pyrene (BaP)-induced cellular carcinogenesis. It was identified that CAR had the ability to eliminate BaP-induced ROS production and subsequent DNA damage. CAR/BaP activated the ROS-mediated phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)Thr308 signaling pathway, whereas the effectors of the PI3K/AKT signaling pathway, murine double minute 2 (MDM2) and p53Ser15, served important functions in the BaP/CAR-mediated MCF10A cellular transformation. The results of the present study indicated that CAR may be a novel chemopreventive agent, notably in the prevention of estrogen receptor-negative breast cancer. The antioxidant effects of CAR may contribute to its chemopreventive activity.

show abstract

Section: Discussionmentioning

confidence: 86%

Carvedilol suppresses malignant proliferation of mammary epithelial cells through inhibition of the ROS‑mediated PI3K/AKT signaling pathway

Liu

Zhang

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Meng et al [ 5 ] demonstrated that MAP kinases and PI3K/AKt/mTor pathways are affected in HCC by the action of CAMK2 γ , causing hyperproliferation of hepatocytes. Other studies demonstrated that IL-6 in HCC is overproduced in malignant transformation of the hepatic tissue [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Flavonoids Effects on Hepatocellular Carcinoma in Murine Models: A Systematic Review

García

Gutierrez

Melo

et al. 2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

The hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. It occurs primarily as manifestation of other pathological processes, such as viral hepatitis, cirrhosis, and toxin exposure that affect directly the cellular process. Studies were selected from PubMed and Scopus databases according to the PRISMA statement. The research filters were constructed using three parameters: flavonoids, hepatocellular carcinoma, and animal model. The bias analysis of the 34 selected works was done using the ARRIVE guidelines. The most widely used flavonoid in the studies was epigallocatechin gallate extracted from green tea. In general, the treatment with different flavonoids presented inhibition of tumor growth and antiangiogenic, antimetastatic, antioxidant, and anti-inflammatory activities. The bias analysis evidenced the absence of methodological processes in all studies, such as the age or weight of the animals, the method of flavonoids' extraction, or the experimental designs, analytical methods, and outcome measures. It has been known that flavonoids have a protective effect against HCC. However, the absence or incomplete characterization of the animal models, treatment protocols, and phytochemical and toxicity analyses impaired the internal validity of the individual studies, making it difficult to determine the effectiveness of plant-derived products in the treatment of HCC.

show abstract

“…Carvedilol is a non-selective anti-oxidant β-blocker used for the reduction of portal blood pressure, prevention of esophageal varices, and reducing the risk of bleeding in chronic liver disease [ 184 ]. Carvedilol possesses potent anti-fibrotic, anti-inflammatory, anti-proliferative, and anti-carcinogenesis properties.…”

Section: Silymarin and Gastrointestinal Cancermentioning

confidence: 99%

“…Carvedilol possesses potent anti-fibrotic, anti-inflammatory, anti-proliferative, and anti-carcinogenesis properties. Balaha and colleagues assessed the possible preventative effects of carvedilol in rats with hepatic cirrhosis who were at risk of progressing to hepatocarcinogenesis [ 184 ]. Carvedilol (10 mg/kg/day) silymarin (50 mg/kg/day), or both were administered to manage hepatic cirrhosis for 69 days.…”

Section: Silymarin and Gastrointestinal Cancermentioning

confidence: 99%

See 1 more Smart Citation

Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer

Fallah

Davoodvandi

Nikmanzar

et al. 2021

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Silymarin contains a group of closely-related flavonolignan compounds including silibinin, and is extracted from Silybum marianum species, also called milk thistle. Silymarin has been shown to protect the liver in both experimental models and clinical studies. The chemopreventive activity of silymarin has shown some efficacy against cancer both in vitro and in vivo. Silymarin can modulate apoptosis in vitro and survival in vivo, by interfering with the expression of cell cycle regulators and apoptosis-associated proteins. In addition to its anti-metastatic activity, silymarin has also been reported to exhibit anti-inflammatory activity. The chemoprotective effects of silymarin and silibinin (its major constituent) suggest they could be applied to reduce the side effects and increase the anti-cancer effects of chemotherapy and radiotherapy in various cancer types, especially in gastrointestinal cancers. This review examines the recent studies and summarizes the mechanistic pathways and down-stream targets of silymarin in the therapy of gastrointestinal cancer.

show abstract

Carvedilol suppresses circulating and hepatic IL-6 responsible for hepatocarcinogenesis of chronically damaged liver in rats

Cited by 17 publications

References 50 publications

Carvedilol suppresses malignant proliferation of mammary epithelial cells through inhibition of the ROS‑mediated PI3K/AKT signaling pathway

Carvedilol suppresses malignant proliferation of mammary epithelial cells through inhibition of the ROS‑mediated PI3K/AKT signaling pathway

Flavonoids Effects on Hepatocellular Carcinoma in Murine Models: A Systematic Review

Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer

Contact Info

Product

Resources

About